Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The two companies will provide integrated support across CMC, non-clinical studies, and clinical operations.
September 17, 2026
By: Patrick Lavery
Editor’s Take: Together, the companies hope to offer a simplified development pathway for biologics and advanced therapies.
ProBio announced a strategic collaboration with Kun Tuo aiming to accelerate investigator-initiated trials (IITs) in China.
The partnership also seeks to streamline clinical operations for global biopharmaceutical companies wanting to advance innovative therapies—again, within China.
ProBio is a global CDMO focusing on biologics and cell and gene therapies (CGTs). Kun Tuo, an IQVIA company, is a leading clinical research organization (CRO) in China.
By collaborating, ProBio and Kun Tuo provide integrated support across chemistry, manufacturing, and controls (CMC), non-clinical studies, and clinical operations. Combined, the companies hope to offer simplified development pathways for biologics and advanced therapies. At the same time, the partnership strives to enable faster and more efficient clinical execution.
“Developers increasingly seek partners who can provide seamless support across the drug development lifecycle,” ProBio CEO Allen Guo said. “This strategic collaboration marks a significant milestone in ProBio’s mission to provide end-to-end solutions for our global customers … We can now offer a seamless pathway from manufacturing to clinical execution, accelerating investigator-initiated trials in China.”
“We are excited to partner with ProBio, a leading CDMO in [this] space,” Kun Tuo General Manager Linda Wang said. “This allows us to combine Kun Tuo’s clinical development expertise in cell and gene therapy with ProBio’s robust manufacturing platform. [It creates] a comprehensive solution that addresses the growing demand for integrated IIT services in China. Together, we will help sponsors navigate the complexities of China’s clinical landscape with greater efficiency and confidence.”
ProBio’s track record includes contributing to more than 1000 good manufacturing practice (GMP) batches of CGT products. The company has supported more than 90 Investigational New Drug (IND) approvals and IIT programs spanning various CGT pipelines.
Kun Tuo employs a workforce of approximately 1000, having supported more than 1400 clinical trials for drugs and medical devices.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
